Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia. more
Time Frame | IXHL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.2% | -1.57% | 0.77% |
1-Month Return | -30.43% | -1.86% | 5.21% |
3-Month Return | -1.78% | -6.07% | 10.43% |
6-Month Return | -45.61% | -0.47% | 13.46% |
1-Year Return | -80.87% | 10% | 32.91% |
3-Year Return | -88.78% | 10.67% | 32.22% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 415.63K | 1.90M | 540.17K | 1.01M | 12.00K | [{"date":"2020-06-30","value":21.9,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":28.47,"profit":true},{"date":"2023-06-30","value":53.43,"profit":true},{"date":"2024-06-30","value":0.63,"profit":true}] |
Cost of Revenue | 309.44K | 911.97K | 4.38K | - | - | [{"date":"2020-06-30","value":33.93,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":0.48,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Gross Profit | 106.19K | 985.63K | 535.79K | 1.01M | 12.00K | [{"date":"2020-06-30","value":10.47,"profit":true},{"date":"2021-06-30","value":97.21,"profit":true},{"date":"2022-06-30","value":52.85,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":1.18,"profit":true}] |
Gross Margin | 25.55% | 51.94% | 99.19% | 100.00% | 100.00% | [{"date":"2020-06-30","value":25.55,"profit":true},{"date":"2021-06-30","value":51.94,"profit":true},{"date":"2022-06-30","value":99.19,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Expenses | 2.96M | 9.22M | 8.37M | 49.67M | 30.05M | [{"date":"2020-06-30","value":5.95,"profit":true},{"date":"2021-06-30","value":18.57,"profit":true},{"date":"2022-06-30","value":16.86,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":60.51,"profit":true}] |
Operating Income | (2.89M) | (8.24M) | (7.84M) | (49.67M) | (30.04M) | [{"date":"2020-06-30","value":-288565421,"profit":false},{"date":"2021-06-30","value":-823933700,"profit":false},{"date":"2022-06-30","value":-783669486,"profit":false},{"date":"2023-06-30","value":-4966800000,"profit":false},{"date":"2024-06-30","value":-3004100000,"profit":false}] |
Total Non-Operating Income/Expense | 150.64K | 78.43K | (2.44M) | 1.22M | 11.82M | [{"date":"2020-06-30","value":1.27,"profit":true},{"date":"2021-06-30","value":0.66,"profit":true},{"date":"2022-06-30","value":-20.68,"profit":false},{"date":"2023-06-30","value":10.32,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Pre-Tax Income | (2.70M) | (8.16M) | (10.29M) | (48.81M) | (18.43M) | [{"date":"2020-06-30","value":-269988937,"profit":false},{"date":"2021-06-30","value":-816359000,"profit":false},{"date":"2022-06-30","value":-1028991200,"profit":false},{"date":"2023-06-30","value":-4881100000,"profit":false},{"date":"2024-06-30","value":-1842900000,"profit":false}] |
Income Taxes | 488.28K | (2.68K) | (3.55M) | - | 30.00K | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-0.55,"profit":false},{"date":"2022-06-30","value":-727.7,"profit":false},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":6.14,"profit":true}] |
Income After Taxes | (3.19M) | (8.16M) | (6.74M) | - | (18.46M) | [{"date":"2020-06-30","value":-318817237,"profit":false},{"date":"2021-06-30","value":-816091100,"profit":false},{"date":"2022-06-30","value":-673667200,"profit":false},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-1845900000,"profit":false}] |
Income From Continuous Operations | (3.93M) | (8.16M) | (21.67M) | (19.98M) | (18.46M) | [{"date":"2020-06-30","value":-392928400,"profit":false},{"date":"2021-06-30","value":-816359000,"profit":false},{"date":"2022-06-30","value":-2166551444,"profit":false},{"date":"2023-06-30","value":-1997955800,"profit":false},{"date":"2024-06-30","value":-1845900000,"profit":false}] |
Income From Discontinued Operations | (768.35K) | - | - | - | - | [{"date":"2020-06-30","value":-76835200,"profit":false},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (3.23M) | (8.16M) | (10.29M) | (48.81M) | (18.46M) | [{"date":"2020-06-30","value":-322783935,"profit":false},{"date":"2021-06-30","value":-816091100,"profit":false},{"date":"2022-06-30","value":-1028991200,"profit":false},{"date":"2023-06-30","value":-4881100000,"profit":false},{"date":"2024-06-30","value":-1845900000,"profit":false}] |
EPS (Diluted) | - | - | - | - | (1.22) | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-122.26,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IXHL | |
---|---|
Current Ratio | 1.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IXHL | |
---|---|
ROA (LTM) | -56.97% |
ROE (LTM) | -115.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IXHL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IXHL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2454.85 |
P/B | 4.47 |
Price/FCF | NM |
EV/R | 305.14 |
EV/Ebitda | NM |
Incannex Healthcare Ltd ADR (IXHL) share price today is $1.665
Yes, Indians can buy shares of Incannex Healthcare Ltd ADR (IXHL) on Vested. To buy Incannex Healthcare Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IXHL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Incannex Healthcare Ltd ADR (IXHL) via the Vested app. You can start investing in Incannex Healthcare Ltd ADR (IXHL) with a minimum investment of $1.
You can invest in shares of Incannex Healthcare Ltd ADR (IXHL) via Vested in three simple steps:
The 52-week high price of Incannex Healthcare Ltd ADR (IXHL) is $8.47. The 52-week low price of Incannex Healthcare Ltd ADR (IXHL) is $1.5.
The price-to-earnings (P/E) ratio of Incannex Healthcare Ltd ADR (IXHL) is
The price-to-book (P/B) ratio of Incannex Healthcare Ltd ADR (IXHL) is 4.47
The dividend yield of Incannex Healthcare Ltd ADR (IXHL) is 0.00%
The market capitalization of Incannex Healthcare Ltd ADR (IXHL) is $29.46M
The stock symbol (or ticker) of Incannex Healthcare Ltd ADR is IXHL